Tag: Biotech and Pharma

Johnson & Johnson (JNJ.N), said on Monday it would buy privately held Halda Therapeutics for $3.05 billion in cash, expanding the medtech conglomerate’s presence in solid tumors and prostate cancer treatments.

Novo Nordisk on Monday said it has cut the direct-to-consumer prices of its blockbuster weight loss drug Wegovy and diabetes counterpart Ozempic, adding to efforts by the company and the Trump administration to make the treatments more accessible.

Shares of Metsera, fell nearly 15% in premarket trading on Monday, after the weight-loss drug developer accepted a sweetened offer from Pfizer, to end a fierce bidding war between the pharma giant and Danish rival Novo Nordisk.

Danish pharmaceutical giant Novo Nordisk said Wednesday it is trimming its growth expectations for its leading obesity and diabetes treatments as competition intensifies and pricing pressures mount in the weight loss market.

Pfizer (PFE.N), on Tuesday raised its full-year profit forecast for the second quarter in a row as robust demand for its blockbuster blood thinner helped it post third-quarter earnings above expectations.

Eli Lilly on Thursday reported third-quarter earnings and revenue that topped estimates and hiked its full-year outlook, as the company continued to see strong demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro.

Merck on Thursday reported third-quarter earnings and revenue that topped estimates as it saw strong demand for its cancer immunotherapy Keytruda.

Eli Lilly (LLY.N), said on Wednesday it is partnering with Walmart (WMT.N), to expand access to Lilly’s weight-loss drug Zepbound, which will be offered for pick-up at Walmart pharmacies nationwide by mid-November.

Eli Lilly and Novo Nordisk stocks fell sharply early Friday after President Donald Trump suggested the price of blockbuster weight-loss medicines could come down substantially.

Abbott missed analysts’ estimates for third-quarter revenue on Wednesday, as weakness in its diagnostics and nutritional businesses failed to offset strong demand for its medical devices, sending its shares down 3% premarket.

Drugmaker Bristol Myers Squibb said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash, aiming to diversify from legacy products facing competition from generic drugs.

 Pfizer (PFE.N) and President Donald Trump on Tuesday said they had cut a deal in which the U.S.-based drugmaker agreed to lower prescription drug prices in the Medicaid program to what it charges in other developed countries in exchange for tariff relief.

 Pfizer (PFE.N), said on Monday it would acquire weight-loss drug developer Metsera (MTSR.O), in a deal valued at up to $7.3 billion, including future payments, to secure its position in the lucrative obesity treatment market.

Ο Όμιλος Lavipharm παρουσιάζει σημαντική αύξηση των ενοποιημένων πωλήσεων το α΄εξάμηνο σύμφωνα με τα οικονομικά αποτελέσματα που δημοσίευσε.

Eli Lilly’s international president said on Wednesday it was too early to assume the company would use the U.S. Food and Drug Administration’s new fast-track review process for its experimental weight-loss pill orforglipron.

Novo Nordisk on Wednesday flagged promising late-stage trial results for its new Cagrilinitide obesity treatment, as the Danish pharmaceutical giant seeks a next-generation alternative to its blockbuster Wegovy weight-loss drug.

Novo Nordisk A/S (NYSE:NVO) stock rose 2.8% in Monday’s premarket trading after the European Medicines Agency approved an update to the Rybelsus label to include cardiovascular benefits for patients with type 2 diabetes.

Danish pharmaceutical giant Novo Nordisk on Wednesday announced plans to cut around 9,000 roles, or roughly 11.5% of its global workforce.

Novartis (NOVN.S), will acquire Tourmaline Bio (TRML.O), for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday.

Eli Lilly’s (LLY.N), blood cancer treatment Jaypirca helped patients live longer without the disease getting worse, the U.S. drugmaker said on Monday, meeting the main goal in a late-stage study in previously untreated patients.